Similar articles for PMID: 7726087

Year	Number of Results
1987	1
1991	5
1992	7
1993	5
1994	17
1995	11
1996	6
1997	8
1998	5
1999	3
2000	1
2001	6
2002	2
2003	4
2004	2
2006	2
2007	1
2008	1
2009	2
2010	2
2011	1
2013	1
2014	4
2015	2
2017	2
2018	1
2019	2
2020	1
2021	2
2024	0

1

The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis.

Yuh WT, Tali ET, Nguyen HD, Simonson TM, Mayr NA, Fisher DJ. Yuh WT, et al. AJNR Am J Neuroradiol. 1995 Feb;16(2):373-80. AJNR Am J Neuroradiol. 1995. PMID: 7726087 Free PMC article. Clinical Trial.

2

Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases.

Yuh WT, Fisher DJ, Runge VM, Atlas SW, Harms SE, Maravilla KR, Mayr NA, Mollman JE, Price AC. Yuh WT, et al. AJNR Am J Neuroradiol. 1994 Jun;15(6):1037-51. AJNR Am J Neuroradiol. 1994. PMID: 8073972 Free PMC article. Clinical Trial.

3

Gadoteridol in multiple sclerosis patients. A comparison of single and triple dose with immediate vs. delayed imaging.

Wolansky LJ, Finden SG, Chang R, Conigliari M, Lee HJ, Shaderowsky PD, Cook SD. Wolansky LJ, et al. Clin Imaging. 1998 Nov-Dec;22(6):385-92. doi: 10.1016/s0899-7071(98)00072-2. Clin Imaging. 1998. PMID: 9876905

4

Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases.

Yuh WT, Engelken JD, Muhonen MG, Mayr NA, Fisher DJ, Ehrhardt JC. Yuh WT, et al. AJNR Am J Neuroradiol. 1992 Jan-Feb;13(1):335-45. AJNR Am J Neuroradiol. 1992. PMID: 1595472 Free PMC article.

5

High-dose gadoteridol in MR imaging of intracranial neoplasms.

Runge VM, Kirsch JE, Burke VJ, Price AC, Nelson KL, Thomas GS, Dean BL, Lee C. Runge VM, et al. J Magn Reson Imaging. 1992 Jan-Feb;2(1):9-18. doi: 10.1002/jmri.1880020103. J Magn Reson Imaging. 1992. PMID: 1623287

6

Enhancement of cerebral diseases: how much contrast agent is enough? Comparison of 0.1, 0.2, and 0.3 mmol/kg gadoteridol at 0.2 T with 0.1 mmol/kg gadoteridol at 1.5 T.

Brekenfeld C, Foert E, Hundt W, Kenn W, Lodeann KP, Gehl HB. Brekenfeld C, et al. Invest Radiol. 2001 May;36(5):266-75. doi: 10.1097/00004424-200105000-00004. Invest Radiol. 2001. PMID: 11323514

7

Brain metastases--comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging.

Akeson P, Larsson EM, Kristoffersen DT, Jonsson E, Holtås S. Akeson P, et al. Acta Radiol. 1995 May;36(3):300-6. Acta Radiol. 1995. PMID: 7742127 Clinical Trial.

8

Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.

Petersein J, Saini S, Mitchell DG, Davis PL, Johnson CD, Kuhlman JE, Parisky YR, Runge VM, Weinreb J, Bernardino ME, et al. Petersein J, et al. AJR Am J Roentgenol. 1995 Nov;165(5):1157-61. doi: 10.2214/ajr.165.5.7572495. AJR Am J Roentgenol. 1995. PMID: 7572495 Clinical Trial.

9

Magnetic resonance imaging of an experimental model of intracranial metastatic disease. A study of lesion detectability.

Runge VM, Wells JW, Williams NM. Runge VM, et al. Invest Radiol. 1994 Dec;29(12):1050-6. doi: 10.1097/00004424-199412000-00007. Invest Radiol. 1994. PMID: 7721546

10

MR imaging detection of cerebral metastases with a single injection of high-dose gadoteridol.

Runge VM, Wells JW, Nelson KL, Linville PM. Runge VM, et al. J Magn Reson Imaging. 1994 Sep-Oct;4(5):669-73. doi: 10.1002/jmri.1880040509. J Magn Reson Imaging. 1994. PMID: 7981511

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

103 results

Results by year